Add Yahoo as a preferred source to see more of our stories on Google. Demis Hassabis speaks during the 56th annual World Economic Forum (WEF) meeting in Davos, Switzerland, January 20, 2026.

Jan 20 (Reuters) - Isomorphic Labs, ‌which uses artificial intelligence ‌for drug discovery, expects to have its first clinical trials by the ‍end of 2026, founder and CEO Demis Hassabis said ⁠on ...

eHealth Africa Academy has graduated 92 students across Nigeria and Africa, building their capacities in advanced javascript and data analytics. The organisation said this was part of its goal to ...

School of Advanced Materials Science and Engineering, Sungkyunkwan University, Suwon 16419, Republic of Korea ...

ABSTRACT: To effectively evaluate a system that performs operations on UML class diagrams, it is essential to cover a large variety of different types of diagrams. The coverage of the diagram space ...

Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind’s AlphaFold breakthrough, the company is pairing ...

Alphabet Inc.'s (NASDAQ:GOOG) (NASDAQ:GOOGL) Isomorphic Labs says its first artificial-intelligence-designed medicines are nearly ready for human testing. What Happened: Isomorphic Labs President ...

Isomorphic Labs, the AI-powered drug company spun out of Google’s DeepMind, just announced that it’s “getting ready” to begin human clinical trials of drugs designed by AI. The news comes as tech ...

Subscribe to Technowize for more insights into the evolving world of technology and the journey of AI across industries.

Add Yahoo as a preferred source to see more of our stories on Google. In April 2025, Isomorphic Labs raised a $600 million in its first-ever external funding round, led by Thrive Capital. Alphabet’s ...

As Isomorphic Labs aims its artificial intelligence tools at drug development, it’s setting up a new outpost in the biotech hub of Cambridge. Founded in 2021 as a spinoff of Alphabet AI company ...